BRISBANE, AUSTRALIA--(Marketwire - Feb 28, 2012) - Alchemia Limited, Inc (ASX: ACL), today announced that Peter Smith, Alchemia's Chief Executive Officer, is scheduled to present at the 32^nd Annual Cowen Health Care Conference in Boston on Monday, March 5, 2012 from 4:30-4:55 PM EST.

Slides from the presentation will be posted to the ASX and available on Alchemia's website at the time of the presentation.

About Alchemia: Alchemia is a drug discovery and development Company founded on its chemistry expertise. The Company's lead drug, fondaparinux (a generic version of GlaxoSmithKline's Arixtra®, a synthetic anticoagulant mainly used for the prevention of deep vein thrombosis), was approved and launched in July 2011 in the U.S. by Alchemia's marketing partner Dr Reddy's Laboratories. Alchemia's pipeline of assets is built on two platform technologies: HyACT® (targeted cancer delivery) and VAST® (drug discovery). The primary objective of the HyACT® technology is to develop a new generation of anti-cancer drugs which demonstrate better efficacy. The lead product from the HyACT® platform is HA-Irinotecan which is currently in a pivotal Phase III clinical trial that commenced recruitment in January 2012.